Eli Lilly has released early Phase 2 data on combining eloralintide, its investigational amylin receptor agonist, with tirzepatide, the dual GLP-1/GIP agonist already approved as Zepbound and Mounjaro. Ahead of presentations planned for the European Association for the Study of Diabetes (EASD) annual meeting, running September 28 through October 2, 2026 in Milan, Lilly reported that adding eloralintide 3 mg to tirzepatide 5 mg produced 17% weight loss over 16 weeks, compared with 10% for tirzepatide 5 mg used alone.
Why Researchers Are Combining an Amylin Drug With a GLP-1 Drug
GLP-1 and GIP receptor agonists like tirzepatide work primarily by slowing digestion and reducing appetite through incretin hormone pathways. Amylin is a separate hormone, co-secreted with insulin, that signals fullness through its own distinct receptor system in the brainstem. Because the two mechanisms are not redundant, researchers have hypothesized that pairing a GLP-1-based drug with an amylin-pathway drug could produce an additive effect on appetite and weight, rather than simply layering more of the same mechanism on top of itself. This site's guide to amylin agonists like eloralintide and cagrilintide covers that mechanism in more detail, and a similar logic underlies Novo Nordisk's cagrilintide-semaglutide combination, CagriSema.
What the Numbers Do and Don't Tell Us
A 7-percentage-point difference in weight loss over just 16 weeks is a meaningful early signal, but this is still a relatively small, short Phase 2 trial rather than a large, multi-year Phase 3 program. Early-phase combination trials like this one are designed mainly to establish dosing and confirm that a signal exists before a much larger trial tests it properly; they are not powered to fully characterize long-term safety, durability, or how the combination performs against other approaches such as CagriSema or higher tirzepatide doses used alone. This site's earlier coverage of eloralintide as a standalone therapy, which reported weight loss up to 20% on its own in a separate Phase 2 trial, provides useful context: combining it with tirzepatide did not simply add the two individual effects together, which is typical of how combination obesity therapies tend to perform in practice.
Regulatory Status
Neither eloralintide nor this specific combination with tirzepatide is FDA-approved. Eloralintide remains an investigational compound in clinical development, and tirzepatide's existing FDA approvals as Zepbound and Mounjaro do not extend to using it together with eloralintide, which has not been studied at the scale or duration the FDA requires for a new approval. Combining an approved drug with an unapproved investigational one is only being done in a controlled clinical trial setting here, not as an approved treatment option.
The Bigger Picture
Lilly's eloralintide-tirzepatide data joins a broader industry trend of testing hormone combinations, rather than single-mechanism drugs, as the next step for obesity treatment, mirroring Novo Nordisk's own combination strategy with CagriSema. Whether combination therapies like this one ultimately outperform newer single-molecule multi-agonists such as retatrutide, which activates three receptors within one compound, remains an open scientific question that will only be answered as larger trials for each approach mature.
People interested in emerging obesity treatments should keep in mind that everything described here is investigational, and should direct questions about currently available, FDA-approved options to a licensed physician.